Search the Newsreel

Vanda (VNDA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President, Chief Executive Officer, and Chairman of the Board - Mihael Polymeropoulos Chief Financial Officer - Kevin Patrick Moran General Counsel - Daniel McGuire Full Conference Call Transcript …

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst

HC Wainwright has significantly cut its Q3 2026 EPS estimate for Vanda Pharmaceuticals (NASDAQ: VNDA) to a loss of $0.61, down from $0.36, and projects a full-year 2026 loss of $3.03 per share, indicating deeper expected losses. This follows Vanda's recent miss on quarterly …

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating

B. Riley has adjusted its price target for Vanda Pharmaceuticals to $12 from $17, while reiterating a "Buy" rating for the company. This news comes amidst other recent updates for Vanda, including their Q2 2026 earnings call, revenue guidance reiteration, and reports of positive …

Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA

Dimensional Fund Advisors LP reduced its stake in Vanda Pharmaceuticals (NASDAQ:VNDA) by 16.4% in the first quarter, selling 346,835 shares but still holding 1.77 million shares valued at $12.24 million. The biopharmaceutical company reported weaker-than-expected Q1 results, with an adjusted loss of $1.04 per …

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price

Vanda Pharmaceuticals Inc. recently reported disappointing second-quarter results, with revenues falling 18% short of analyst estimates and statutory losses exceeding expectations. Following this, analysts have downgraded revenue forecasts, increased projected per-share losses, and cut the consensus price target by 12% to US$12.44, reflecting concerns …

Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen

Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline

Vanda Pharmaceuticals reported a wider second-quarter 2026 net loss of $62.5 million, up from $27.2 million a year prior, as operating expenses surged to $114.3 million. Revenue declined 4% to $50.5 million, primarily due to a 66% drop in Hetlioz sales, while Fanapt sales …

Vanda Pharmaceuticals Inc. Quarterly Earnings Report

Vanda Pharmaceuticals Inc. (VNDA) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Vanda Pharmaceuticals Inc. (VNDA), including its current stock price, recent news, financial statistics, and historical data. It details the company's product portfolio and pipeline, financial performance metrics, analyst ratings, and comparisons with similar biotechnology companies. The …

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary

Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen

Vanda Pharmaceuticals reported a wider-than-expected loss and lower-than-forecast revenue for Q2 2026, driven by a sharp decline in HETLIOZ sales despite growth in Fanapt and PONVORY. The company missed analyst estimates with an adjusted loss of $1.04 per share on revenue of $50.5 million, …

Is Vanda Pharmaceuticals (VNDA) Facing Growth Challenges After Q

VANDA PHARMACEUTICALS ($VNDA) Releases Q2 2026 Earnings, Stock Rises

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals announced its second quarter 2026 financial results, highlighting a 23% increase in Fanapt® net product sales to $36.0 million and forecasting full-year 2026 total revenue between $240-$290 million. The company reported a cash balance of $170.0 million, expected to fund operations through …

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) reported a Q2 loss of $1.04 per share, significantly missing the Zacks Consensus Estimate of a $0.51 loss, and also lagged revenue estimates with $50.53 million against an expected $62.67 million. The company's shares have fallen almost 40% year-to-date, and its …

Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS

Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview

Vanda Pharmaceuticals Inc is projected to report a loss of 59 cents per share. This information is part of an earnings preview. The full article by Refinitiv is available on TradingView.

Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Vanda Pharmaceuticals (NASDAQ: VNDA) had 561 employees worldwide as of March 2026, marking a 107.9% growth since 2023. The company is actively hiring, with 218 active job postings in 2026, and its workforce is primarily concentrated in North America, with Engineering being the largest …

Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m.

Vanda Pharmaceuticals (Nasdaq: VNDA) is scheduled to release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and corporate …

Vanda Pharma (VNDA.US) Stock Price, Quote & News

This article provides an overview of Vanda Pharmaceuticals Inc. (VNDA.US) stock information, including its current price ($5.050), daily performance, and trading metrics. It also presents analyst ratings with a price forecast of $14.13 and a "Buy" consensus, along with recent news updates pertaining to …

Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence

Vanda Pharmaceuticals Inc (VNDA) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 1.13% quarter-over-quarter to 78.40%, with James Simons being the largest institutional shareholder holding …

Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Vanda Pharmaceuticals Inc (VNDA), highlighting its business segments and regional contributions. The data, updated on April 6, shows that the company's revenue is primarily driven by products such as Fanapt, Hetlioz, and PONVORY, with all revenue …

VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100

This article provides a comprehensive stock analysis of Vanda Pharmaceuticals Inc (VNDA) using TradingKey's stock score. It highlights the company's stable fundamentals, high growth potential, and fair valuation which ranks 78th in the Biotechnology & Medical Research industry. Despite recent weak stock market performance, …

Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis

Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, positioning it 208th out of 386 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.32, which is significantly below its recent high and above its recent low. Key …

Vanda Pharmaceuticals (VNDA) to Post Earnings on Thursday

B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $17

B. Riley Securities has reiterated its Buy rating for Vanda Pharmaceuticals (VNDA.US), maintaining its target price at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

ETFs Investing in Vanda Pharmaceuticals Inc. Stocks

This article lists various ETFs that hold Vanda Pharmaceuticals Inc. (VNDA) stocks, providing detailed financial information for each fund. The data includes market value, weight of VNDA in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), current price, daily percentage …

Vanda Pharmaceuticals - Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

Vanda Pharmaceuticals is being downgraded to "Hold" due to increasing financial losses, significant cash burn, and uncertainties surrounding its pipeline execution. While Fanapt revenues are growing, the impending patent expiry and decline in Hetlioz sales pose a threat to near-term revenue stability. Although Bysanti …

Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP

Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion for Orphan Drug Designation of Imsidolimab. This designation is for the treatment of Generalized Pustular Psoriasis (GPP). This news was reported by Reuters.

EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease

Vanda Pharmaceuticals announced that the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for its investigational product, imsidolimab, for the treatment of generalized pustular psoriasis (GPP). This marks the first time the EMA has recognized a GPP treatment with …

Insider Sellers Might Regret Selling Vanda Pharmaceuticals Shares at a Lower Price Than Current Market Value

Insiders of Vanda Pharmaceuticals Inc. sold US$2.8 million worth of stock over the last year at an average price of US$8.20, which is lower than the current share price but still higher than the latest price of US$5.85 after an 11% value drop. Despite …

Vanda Pharmaceuticals To Be Primary Sponsor Of Schumacher’s INDYCAR Entry For Four Races; Schumacher to Pilot the No. 47 NEREUS™ Honda at events in Nashville, Portland, Washington D.C. and Monterey

Vanda Pharmaceuticals will be the primary sponsor for Mick Schumacher's No. 47 NTT INDYCAR SERIES entry in four races in 2026: Nashville, Portland, Washington D.C., and Monterey. Vanda will feature its NEREUS™ product, an oral neurokinin-1 receptor antagonist for preventing motion-induced vomiting, on Schumacher's …